Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26351456
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical
Applications Based on Current Evidence
#MMPMID26351456
Zalpour A
; Oo TH
Adv Hematol
2015[]; 2015
(?): 920361
PMID26351456
show ga
Vitamin K antagonists (VKA) and heparins have been utilized for the prevention
and treatment of thromboembolism (arterial and venous) for decades. Targeting and
inhibiting specific coagulation factors have led to new discoveries in the
pharmacotherapy of thromboembolism management. These targeted anticoagulants are
known as direct oral anticoagulants (DOACs). Two pharmacologically distinct
classes of targeted agents are dabigatran etexilate (Direct Thrombin Inhibitor
(DTI)) and rivaroxaban, apixaban, and edoxaban (direct oral factor Xa inhibitors
(OFXaIs)). Emerging evidence from the clinical trials has shown that DOACs are
noninferior to VKA or low-molecular-weight heparins in the prevention and
treatment of thromboembolism. This review examines the role of edoxaban, a
recently approved OFXaI, in the prevention and treatment of thromboembolism based
on the available published literature. The management of edoxaban in the
perioperative setting, reversibility in bleeding cases, its role in cancer
patients, the relevance of drug-drug interactions, patient satisfaction,
financial impacts, and patient education will be discussed.
free
free
free
